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S U M M A R Y
The development of macrolide resistance that occurred during 3 days of therapy with azithromycin to
treat Mycoplasma pneumoniae pneumonia in a paediatric patient is reported. After extended molecular
characterization of strains, the parallel occurrence of clones showing the non-mutated wild-type 23S
rRNA sequence as well as mutations A2063G and A2064G, which are both responsible for phenotypic
resistance, was conﬁrmed for the ﬁrst time.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Mycoplasma pneumoniae is a frequent cause of respiratory tract
infection in humans, resulting in disease that ranges from mild
forms of tracheobronchitis to cases of severe interstitial pneumo-
nia. Although all age groups can be infected, most cases have been
reported in older children. In epidemic phases occurring every 5 to
7 years, up to 40% of all cases of community-acquired pneumonia
are attributed to M. pneumoniae. Furthermore, extrapulmonary
complications have been described, mainly involving the skin and
central nervous system.1
Mycoplasmas lack a cell wall and thus are intrinsically resistant
to beta-lactam and all other antibiotics that target the cell wall.
Quinolones, tetracyclines, and macrolides represent the therapeu-
tic options. With respect to side effects, the latter antibiotics are
the treatment of choice for paediatric patients. Unfortunately,
since the year 2000 the emergence of resistant strains has become
a growing problem. Macrolide resistance in M. pneumoniae is based
exclusively on mutations of single-copy 23S rRNA. The A2063G/C
or A2064G/C transitions are the most common point mutations* Corresponding author. Tel.: +49 351 4586577; fax: +49 351 4586310.
E-mail address: roger.dumke@tu-dresden.de (R. Dumke).
http://dx.doi.org/10.1016/j.ijid.2014.07.014
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).described to date, and in all strains tested they lead to a high level
of resistance (minimum inhibitory concentration (MIC) >32 mg/l)
to the different classes of macrolide antibiotics.2 Since culture of M.
pneumoniae is time-consuming and limited to a few laboratories
worldwide, many studies have conﬁrmed the phenotypic resis-
tance of mutated strains with molecular methods. These have
become a major tool for the detection of resistant strains. With
rates of >90%, macrolide resistance is at a critical level in several
Asian countries, whereas the rates of mutated strains in Europe
and the USA have remained <10%.2 Nevertheless, the circulation of
small numbers of resistant strains in the human population
requires the periodic monitoring of M. pneumoniae-positive
respiratory samples, as well as further investigation of the
mechanisms of emerging resistance.
Here, we describe the course of M. pneumoniae pneumonia in a
boy with severe pre-existing conditions, showing the failure of
macrolide therapy with special respect to the molecular charac-
terization of the Mycoplasma strain.
2. Case report
A 15-year-old boy (co-morbidities: epilepsy, spastic tetraplegia,
asphyxia, dystrophy necessitating percutaneous endoscopic gas-
trostomy (PEG), and recurrent pneumonia) was referred to hospitalciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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for 7 days, persistent fever up to 40.6 8C, and crepitations on lung
examination. Candida albicans was detected in swabs of the PEG
tube. C-reactive protein (CRP) was 60.2 mg/l. Before admission to
the hospital, the patient had been treated with cefuroxime axetil.
He had not received any macrolides prior to admission.
The pharyngeal swab taken on the ﬁrst day of hospitalization
was positive for M. pneumoniae using real-time PCR (cycle
threshold (Ct) value: 22.0). Antibiotic therapy was changed to
azithromycin (11 mg/kg/day) for 3 days and oxygen was adminis-
tered overnight. After 9 days of hospitalization the boy was
discharged to ambulant care.
On day 19, the patient presented again because of severe
multiple skin inﬂammations (especially in the genital region),
persistent cough, and recurrence of high fever (up to 40.0 8C). CRP
was 18.0 mg/ml. M. pneumoniae real-time PCR from the pharyngeal
swab was still positive (Ct value: 23.8). Respiratory specimens
were negative for Chlamydia spp, respiratory syncytial virus,
human metapneumovirus, and adenovirus. Swabs from the
affected skin regions were taken and were positive for Proteus
mirabilis, Staphylococcus aureus, C. albicans, and Pseudomonas
aeruginosa, and PEG tube swabs were positive for P. aeruginosa
and C. albicans. To treat these multiple infections caused by a broad
spectrum of microorganisms and to minimize the risk of sepsis due
to P. aeruginosa, intravenous therapy with tobramycin and
ampicillin/sulbactam was given. All further respiratory samples
taken after the antibiotic treatment were found to be negative for
M. pneumoniae. The patient was discharged in satisfactory general
condition on day 34 after the start of the ﬁrst hospitalization.
M. pneumoniae strains in the samples taken on day 1 (sample 1,
ﬁrst hospitalization) and day 19 (sample 2, second hospitalization)
were investigated for mutations in the 23S rRNA and genotyped as
described. The sequencing results of sample 1 showed a 23S rRNA
sequence with no resistance-relevant mutations (Table 1), indi-
cating a macrolide-susceptible M. pneumoniae strain. In contrast, in
the specimen sampled after the patient had been treated with
azithromycin, mutations at positions 2063 and 2064 of 23S rRNA
and the wild-type sequence were suggested. To prove this, the PCR
products were cloned into Escherichia coli using a TOPO Cloning Kit
(Invitrogen, Carlsbad, CA, USA); the manufacturer’s instructions
were followed. Colourless colonies were picked for ampliﬁcation of
the region of interest of M. pneumoniae-speciﬁc 23S rRNA and theTable 1
Results of molecular characterization of Mycoplasma pneumoniae in respiratory tract sa
Sample (description) Typing of M. pneumoniae strain 
(arrows: position
2063/2064)
VNTR type VN
P1 
1 Subtype 1 4/4/5/7/2 7 
(Day 1; before treatment
with azithromycin)
2 Subtype 1 4/4/5/7/2 7 
(Day 19; 16 days after the end of
treatment with azithromycin)products were sequenced. In contrast to sample 1 (wild-type 23S
rRNA sequence), results from sample 2 conﬁrmed a mixture of
genotypes, showing the wild-type sequence and clones with two
mutations typical for a macrolide-resistant strain. Furthermore,
the strains in both samples were investigated with different
methods for typing of M. pneumoniae. Genotyping revealed
identical results for the two specimens, suggesting that the
macrolide-resistant mutants were selected from wild-type Myco-
plasma. P1 and VNTR types of strain were found both in macrolide-
resistant and susceptible mycoplasmas, conﬁrming the absence of
particular clones showing macrolide resistance.1,2
3. Discussion
The development of macrolide resistance in M. pneumoniae
after adequate antibiotic treatment appears to be a rare event. In a
recent Swedish study, resistance of the strain after treatment with
macrolides was demonstrated in only one of 22 patients.3 In most
cases, persistent symptoms after antibiotic therapy are the reason
for additional diagnostic procedures. Interestingly, 9 days after the
end of therapy, macrolide-susceptible as well as macrolide-
resistant strains were detected in the patient presented here. It
might be assumed that the treatment was not able to induce
resistance in all mycoplasmas colonizing the host. Subtyping of
strains in both samples showed no evidence of an independent
second infection. Although the co-occurrence of mutated and non-
mutated clones in one sample has already been described,4 this is
the ﬁrst time that a mixture of genotypes showing different
mutations that cause macrolide resistance in M. pneumoniae has
been detected. From a diagnostic point of view, the results of real-
time PCR with melting point analysis for the detection of
macrolide-resistant strains, as well as sequencing results to
conﬁrm a resistant M. pneumoniae strain, should be interpreted
with caution. The demonstrated transitions led to comparable
levels of resistance against azithromycin.2
In conclusion, the use of macrolides in paediatric patients with
severe pneumonia can generally be recommended in countries
with a low rate of resistant M. pneumoniae strains, such as those of
Europe and the USA.1,2 Paediatric patients with conﬁrmed M.
pneumoniae infection, an unsatisfactory response to macrolide
treatment, and severe co-morbidities like the patient presented
here should undergo additional diagnostic investigations and amples taken from the patient at different time-points
Mutation in 23S rRNA Result of cloning (%)
TR
type
None No mutation (100)
Two A2063G (46)
A2064G (28)
No mutation (26)
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caused by macrolide-resistant M. pneumoniae strains are charac-
terized by prolonged respiratory symptoms and extended hospital
stays compared with infections due to macrolide-susceptible
mycoplasmas.1,2 The decision to use alternative antibiotics should
be assessed carefully and will depend mainly on the severity of the
clinical symptoms.
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